Study Summary
This trial will test a drug for treating agitation in people with dementia, up to 168 doses in 12 weeks.
- Dementia
- Agitation
Treatment Effectiveness
Effectiveness Progress
Study Objectives
0 Primary · 1 Secondary · Reporting Duration: 30 minutes post-dose for first episode of agitation
Trial Safety
Safety Progress
Side Effects for
Trial Design
3 Treatment Groups
Cohort 1- 40 Micrograms
1 of 3
Cohort 2- 60 Micrograms
1 of 3
Placebo
1 of 3
Experimental Treatment
Non-Treatment Group
150 Total Participants · 3 Treatment Groups
Primary Treatment: Cohort 1- 40 Micrograms · Has Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 65+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What hazards are associated with a Cohort 1- 40 Micrograms protocol?
"Based on the available research, Cohort 1- 40 Micrograms received a score of 3 in terms of safety. This is due to Phase 3 trials that have been conducted with positive results both in efficacy and overall risk assessment." - Anonymous Online Contributor
Are there still available opportunities to participate in this research?
"As indicated on clinicaltrials.gov, the recruitment for this medical trial is still ongoing; it was initially posted on December 14th 2022 and recently updated on December 16th 2022." - Anonymous Online Contributor
What is the maximum capacity of participants for this trial?
"Correct. The clinicaltrials.gov database implies that this experiment is accepting patients, with the original posting dating back to December 14th 2022 and last updated on December 16th 2022. This research requires 150 individuals to be recruited at one study site." - Anonymous Online Contributor